Applications Published 10 October 2001
Published: 16-Jun-2002
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT).
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT).
Exo-2-mecamylamine formulation for use in treatment
University of South Florida 1139743*Exo-R-mecamylamine formulation and use in treatment
University of South Florida 1139744*Compounds and methods for the treatment of ariway diseases and for the delivery of airway drugs
The University of North Carolina at Chapel Hill 1139748*Bone sialoprotein based toxic gene therapy for the treatment of calcified tumours and tissues
The University of Virginia Alumni Patents Foundation 1139749*Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
Arch Development 1139751*Methods and compsns for treatment of cell proliferative disorders.
Marine Polymer Technologies 1139752*Formulations for treating disease and methods of using same
Nitrosystems 1139753* 3-heteroarylidenyl-2-indolene compounds for modulating protein kinase activity and for use in cancer chemotherapy
Sugen 1139754* Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
Pathogenesis 1139755*Synergistic antimicrobial combination of 4,5-dichloro-2-N-octyl-4-isothiazolin-3-one and a mixture of chlorinated isocyanurate and a bromide compound and methods of using same
Calgon 1139757*Pharmaceutical compsn for oral administration designed to prevent misuse at the espense of a thrid party
Sanofi-Synthelabo 1140011* Conversin of liquid filled gelatin capsules into controlled release systems by multiple coatings
Alza 1140012*Foaming antacid suspension tablets
Dr Regenold 1140013*Polynucleotide compsns for intramuscular and intradermal administration
Supratex Pharma 1140015*Water-insoluble drug delivery system
The United States of America, as represented by the Secretary of the Department of Health & Human Services 1140017*Polyol/oil suspension for the sustained release of proteins
Amgen 1140018* Aerosol formulations for buccal and pulmonary application
Generex Pharmaceuticals 1140019* Large molecule drug delivery system using aerosolised membrane-mimetic amphiphiles
Generex Pharmaceuticals 1140020*Improved formulation for topical non-invasive application in vivo
Idea 1140021*Method of administering a compound to multi-drug resistant cells
Madasit Medical Research Services & Development 1140022* Integrative protein-DNA cochleate formulations and methods for transforming cells
University of Maryland; University of Medicine and Dentistry of New Jersey 1140023*Particles and oral delivery of peptides and processes
Regents of the University of California 1140024*Granules for oral administration, process for producing the same, and tablets produced from the granules
Calpis 1140025*Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same
Aventis Pharmaceuticals 1140026*Dosage forms comprising porous particles
Alza 11040027*Methods for treating ovarian cancer, poly(phosphoester) compsns, and biodegradable articles for same
Guilford Pharmaceuticals 1140028*Preparation of microparticles having a selected release profile
Alkermes Controlled Therapeutics 1140029* Medicament forms having controlled release and containing active substances which easily dissolve in water
Knoll 1140030*Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
Hexal 1140031*A pharmaceutical mixture comprising a profen
Knoll 1140032*Improved controlled release compsns and method
Amcol International 1140033* Controlled release formulation of divaproex sodium
Abbott Laboratories 1140034*Method for preparing an effervescent granulate comprising iron gluconate, granulate thus obtained and tablets containing the same
E-Pharma Trento 1140035*Novel formulations comprising lipid-regulating agents
Abbott Laboratories 1140036* Multiparticulate oral dosage forms
Elan Corp 1140037*Transdermal drug delivery system
Dermatech 1140038*Transparent transdermal nicotine delivery devices
Alza 1140039*Methods for treating conditions associated with the accumulation of excess extracellular matrix
The University of Utah Research Foundation; American National Red Cross 1140041*Utilisation of inhibitors of the KQT1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites
Aventis Pharma 1140042*Transgenic plants comprising a conditionally lethal gene
National Research Council Canada 1140043*CGMP PDE 5 inhibitors for inhalation in the treatment of sexual dysfunction
Novartis 1140044* Homer a new target of treating psychiatric disorders
Knoll 1140045*Use of a MEK inhibitor for preventing transplant rejection
Warner-Lambert 1140046* Endocrine therapy for breats cancer: combined treatment with tamoxifen plus alkyl PCDFs
The Texas A&M University System 1140047*Methods for treating certain diseases using naaladase inhibitors
Guilford Pharmaceuticals 1140048*Compsns and methods to inactivate N-type calcium channels
Neuromed Technologies 1140049*A compsn useful to treat periodontal disease
1333366 Ontario 1140050*Use of tertbutylhydroquionone for lowering blood cholesterol and/or blood triglycerides
Eastman Chemical 1140051* Sensitising agents for the treatment of skin lesions
Panacea Pharmaceuticals 1140052* Compsn and method for enhancing male fertility and libido
Bendera, Richard J; Wilson, Leanna S 1140053*Bretylium compsns and kits, and their use in preventing and treating cardiovascular conditions
Bacaner, Marvin B; Kreevoy, Maurice M 1140054*Use of a 5HT 2A and 5HT 2a/C receptor antagonist for preparing medicines for treating snoring and high resistance syndrome of upper anatomical airways
Sanofi-Synthelabo 1140055* The utilisation of inhibitors of the sodium hydrogen exchanger for producing a medicament for preventing organ dysfunctions and diseases related toa particular age and for prolonging life
Aventis Pharma Deutschland 1140056*Pharmaceutical compsn containing metformin acarbose or glimepiride and optionally poly(dimethyl)-siloxane
Hexal 1140057*Pharmaceutical aerosol formulations containing fluoroalkanes, budesonide
Baker Norton Pharmaceuticals 1140059*Use of a nitrosourea derivatives for prevention or treatment of acute allograft rejection
Southern Research Institute 1140060*Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Orphan Medical 1140061* Treatment of asthma with MEK inhibitors
Warner-Lambert 1140062*Method and compsn for the maintenance and restitution of gut integrity
American Home Products 1140063*Oral administration of taxoid derivatives
Aventis Pharma 1140064*Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease
Loma Linda University Medical Centre 1140065*Nitrosated and nitrosylated H2 receptor antagonist compounds, compsns and methods of use
Nitromed 1140066*Antiviral method using MEK inhibitors
Warner-Lambert 1140067*Doramectin formulations
Pfizer 1140068*Compounds which affect MRNA stability and uses thereof
Novation Pharmaceuticals 1140069*Treatment of conditions with a need for the inhibition of GSK-3
SmithKline Beecham 1140070*Use of AT-1 receptor antagonist or At-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptor
Novartis 1140071*Compounds and methods
SmithKline Beecham 1140072*Combination of farnesyl transferase inhibitors and irinotecan or camptothecin for treating cancer
Aventis Pharma 1140073*Indole and indolizidine derivatives for the treatment of migraine
NPS Allelix 1140074*Treatment of retroviral infections with oxyphenbutazone
A-Viral 1140075*Use of 5HT3-receptor antagonists for the treatment of chronic fatigue syndrome
Novartis Pharma 1140076*Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
Maxim Pharmaceuticals 1140077*Benzimidazole vascular damaging agents
Angiogene Pharmaceuticals 1140078* Use of riluzole for treating acoustic traumas
Aventis Pharma 1140080* Improving mental performance by increasing brain insulin sensitivity
Mindset Biopharmaceuticals 1140081*
